Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285029478> ?p ?o ?g. }
- W4285029478 endingPage "3361" @default.
- W4285029478 startingPage "3361" @default.
- W4285029478 abstract "Triple-negative breast cancers (TNBC) expressing PD-L1 qualify for checkpoint inhibitor immunotherapy. Cyclin E/CDK2 is a potential target axis in TNBC; however, small-molecule drugs at efficacious doses may be associated with toxicity, and treatment alongside immunotherapy requires investigation. We evaluated CDK inhibition at suboptimal levels and its anti-tumor and immunomodulatory effects. Transcriptomic analyses of primary breast cancers confirmed higher cyclin E/CDK2 expression in TNBC compared with non-TNBC. Out of the three CDK2-targeting inhibitors tested, the CDK 2, 7 and 9 inhibitor SNS-032 was the most potent in reducing TNBC cell viability and exerted cytotoxicity against all eight TNBC cell lines evaluated in vitro. Suboptimal SNS-032 dosing elevated cell surface PD-L1 expression in surviving TNBC cells. In mice engrafted with human immune cells and challenged with human MDA-MB-231 TNBC xenografts in mammary fat pads, suboptimal SNS-032 dosing partially restricted tumor growth, enhanced the tumor infiltration of human CD45+ immune cells and elevated cell surface PD-L1 expression in surviving cancer cells. In tumor-bearing mice engrafted with human immune cells, the anti-PD-L1 antibody avelumab, given sequentially following suboptimal SNS-032 dosing, reduced tumor growth compared with SNS-032 alone or with avelumab without prior SNS-032 priming. CDK inhibition at suboptimal doses promotes immune cell recruitment to tumors, PD-L1 expression by surviving TNBC cells and may complement immunotherapy." @default.
- W4285029478 created "2022-07-12" @default.
- W4285029478 creator A5007426675 @default.
- W4285029478 creator A5013066121 @default.
- W4285029478 creator A5014075850 @default.
- W4285029478 creator A5019611893 @default.
- W4285029478 creator A5019992879 @default.
- W4285029478 creator A5024753308 @default.
- W4285029478 creator A5047287597 @default.
- W4285029478 creator A5048636641 @default.
- W4285029478 creator A5054103832 @default.
- W4285029478 creator A5064339857 @default.
- W4285029478 creator A5071903220 @default.
- W4285029478 creator A5073396282 @default.
- W4285029478 creator A5075094413 @default.
- W4285029478 creator A5079578038 @default.
- W4285029478 creator A5084589458 @default.
- W4285029478 date "2022-07-11" @default.
- W4285029478 modified "2023-09-26" @default.
- W4285029478 title "CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models" @default.
- W4285029478 cites W1972014613 @default.
- W4285029478 cites W1984545852 @default.
- W4285029478 cites W1985987855 @default.
- W4285029478 cites W2000302922 @default.
- W4285029478 cites W2004630197 @default.
- W4285029478 cites W2005895632 @default.
- W4285029478 cites W2007618242 @default.
- W4285029478 cites W2012034410 @default.
- W4285029478 cites W2015383124 @default.
- W4285029478 cites W2043398720 @default.
- W4285029478 cites W2044702943 @default.
- W4285029478 cites W2046024621 @default.
- W4285029478 cites W2052888848 @default.
- W4285029478 cites W2063264144 @default.
- W4285029478 cites W2066671159 @default.
- W4285029478 cites W2085934079 @default.
- W4285029478 cites W2089026309 @default.
- W4285029478 cites W2089353165 @default.
- W4285029478 cites W2096283457 @default.
- W4285029478 cites W2096322385 @default.
- W4285029478 cites W2097255042 @default.
- W4285029478 cites W2100413206 @default.
- W4285029478 cites W2107556275 @default.
- W4285029478 cites W2110818745 @default.
- W4285029478 cites W2121594851 @default.
- W4285029478 cites W2127111173 @default.
- W4285029478 cites W2129030357 @default.
- W4285029478 cites W2132619562 @default.
- W4285029478 cites W2136028462 @default.
- W4285029478 cites W2137564436 @default.
- W4285029478 cites W2143336748 @default.
- W4285029478 cites W2149472508 @default.
- W4285029478 cites W2154626333 @default.
- W4285029478 cites W2158108546 @default.
- W4285029478 cites W2159937349 @default.
- W4285029478 cites W2161382947 @default.
- W4285029478 cites W2167292349 @default.
- W4285029478 cites W2198360076 @default.
- W4285029478 cites W2259802687 @default.
- W4285029478 cites W2309969893 @default.
- W4285029478 cites W2345415641 @default.
- W4285029478 cites W2394186663 @default.
- W4285029478 cites W2402566748 @default.
- W4285029478 cites W2504613444 @default.
- W4285029478 cites W2536094308 @default.
- W4285029478 cites W2560367415 @default.
- W4285029478 cites W2607129810 @default.
- W4285029478 cites W2612431515 @default.
- W4285029478 cites W2625001374 @default.
- W4285029478 cites W2750328162 @default.
- W4285029478 cites W2766673799 @default.
- W4285029478 cites W2766676715 @default.
- W4285029478 cites W2768547338 @default.
- W4285029478 cites W2769376007 @default.
- W4285029478 cites W2772037929 @default.
- W4285029478 cites W2781879617 @default.
- W4285029478 cites W2783507731 @default.
- W4285029478 cites W2789574985 @default.
- W4285029478 cites W2792561054 @default.
- W4285029478 cites W2803648292 @default.
- W4285029478 cites W2887583339 @default.
- W4285029478 cites W2891365914 @default.
- W4285029478 cites W2897422388 @default.
- W4285029478 cites W2898918507 @default.
- W4285029478 cites W2902530914 @default.
- W4285029478 cites W2902655481 @default.
- W4285029478 cites W2903216749 @default.
- W4285029478 cites W2918171974 @default.
- W4285029478 cites W2944687997 @default.
- W4285029478 cites W2953287793 @default.
- W4285029478 cites W2984179939 @default.
- W4285029478 cites W2990391624 @default.
- W4285029478 cites W2990398119 @default.
- W4285029478 cites W3022464154 @default.
- W4285029478 cites W3022978907 @default.
- W4285029478 cites W3039765163 @default.
- W4285029478 cites W3044594121 @default.
- W4285029478 cites W3118458553 @default.